CD4 and neoplasm: Consistently, our recent study revealed that immunizations with nonreplicable MC38 CRC cells plus rGRA6Nt adjuvant potently activate not only CD8+ cytotoxic T cells but also IFN-γ production of both CD4+ and CD8+ T cells specifically to the tumor cells16.